|Day Low/High||4.05 / 4.24|
|52 Wk Low/High||2.20 / 9.90|
--RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) is a potential first-in-class pharmacologic treatment option for acquired blepharoptosis (droopy eyelid)--
Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.
SAN DIEGO, July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial public...
Law Offices of Howard G. Smith announces an investigation on behalf of Osmotica Pharmaceuticals plc investors ("Osmotica" or the "Company") (NASDAQ: OSMT) concerning the Company and its officers' possible violations of federal securities laws.
Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (NASDAQ: OSMT) complied with federal securities laws.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.